Beyond Hemoglobin S: Systems Biology Insights into the Multisystem Nature of Sickle Cell Disease: A Narrative Review

Abstract

Background: Sickle cell disease (SCD) is classically defined by a single-point mutation in the β-globin gene leading to hemoglobin S polymerization and erythrocyte sickling. However, accumulating evidence indicates that SCD is a complex multisystem disorder characterized by chronic inflammation, endothelial dysfunction, immune dysregulation, metabolic reprogramming, and progressive multiorgan injury. This expanded pathophysiological framework is necessary to explain the marked clinical heterogeneity, variable organ involvement, and differential therapeutic responses observed across individuals and populations. Objective: To synthesize and critically appraise systems biology evidence elucidating the multisystem nature of SCD, and to highlight translational implications for biomarker discovery, precision therapeutics, and implementation of disease-modifying and curative strategies. Methods: A narrative literature review was conducted across PubMed/MEDLINE, Scopus and Web of Science to identify peer-reviewed articles published up to 2025. Search terms included combinations of “sickle cell disease,” “systems biology,” “multi-omics,” “genomics,” “transcriptomics,” “proteomics,” “metabolomics,” “endothelial dysfunction,” “inflammation,” and “precision medicine.” Original research articles, systematic reviews, narrative reviews, and relevant clinical guidelines were considered. Studies were thematically synthesized into biological domains (vascular–endothelial, immune–inflammatory, metabolic–redox, genomic–epigenomic, neuroendocrine, and host–microbiome interactions). Emphasis was placed on integrative and network-based analyses, translational relevance, and evidence linking molecular networks to clinical phenotypes and outcomes. Results: Systems-level analyses reveal that SCD pathobiology is organized around interconnected networks involving endothelial activation, leukocyte–platelet–erythrocyte interactions, chronic innate immune signaling, coagulation pathway activation, and redox imbalance. Multi-omics studies demonstrate coordinated metabolic reprogramming and persistent inflammatory signatures that extend beyond acute vaso-occlusive episodes into chronic vasculopathy and organ dysfunction. Genomic and epigenomic modifiers, including regulators of fetal hemoglobin and inflammatory pathways, contribute substantially to phenotypic heterogeneity and organ-specific risk. Emerging evidence implicates neuroendocrine dysregulation and host–microbiome interactions as modulators of systemic inflammation and vaso-occlusive susceptibility. Integrative biomarker panels and network-informed therapeutic strategies show promise for improved risk stratification and personalized intervention. Conclusion: Beyond hemoglobin S polymerization, SCD is best understood as a dynamic, multisystem network disease. Systems biology provides a unifying framework to reconcile molecular complexity with clinical heterogeneity and offers actionable pathways for biomarker development, precision therapeutics, and optimization of curative interventions. Embedding systems-level insights into clinical practice and health system design—particularly in high-burden, resource-limited settings—is essential for achieving equitable, durable improvements in SCD outcomes.